Who We Are
What We Do
Corporate Responsibility
Patients and HCPS
Contact us
Careers | Investors | Patients and HCPS | Contact us
Careers Investors Patients and HCPS Contact us
Home / Company News / Gan & Lee Pharmaceuticals Shines at the 22nd CPHI China
Gan & Lee Pharmaceuticals Shines at the 22nd CPHI China

From June 17 to 19, 2024, the 22nd CPHI China was held at the Shanghai New International Expo Center. Gan & Lee Pharmaceuticals (referred to as Gan & Lee, stock code: 603087. SH) made a strong impression with a comprehensive showcase of their insulin products and medical devices. The company presented its latest achievements in R&D, production processes, and international commercialization to industry peers and global customers.

The booth of Gan & Lee was designed with a focus on interaction and innovation, providing attendees with a hands-on product experience. The display area featured various insulin injections, pre-filled pens, and related devices such as insulin pens and needles, drawing significant interest from visitors and customers alike.

On the first evening of the exhibition, Liu Gai, the International Business Director of Gan & Lee Pharmaceuticals, attended the "CPHI Celebration Awards & Networking Party" at the Kerry Hotel Pudong, Shanghai. This event celebrates companies that demonstrate innovation and significant contributions to the industry. Gan & Lee received the CPHI Global Partner Award, recognizing its outstanding performance and the widespread acclaim of its products and services in the global market.

The next day, CEO Du Kai led the international business team to the Russia-China Pharmaceutical Cooperation Forum 2024, also held at the Kerry Hotel Pudong. This forum brought together key representatives from the Russian Ministry of Industry and Trade, Chinese regulatory bodies, and the Russian Ministry of Health. Discussions centered on enhancing the comprehensive strategic cooperation between China and Russia, particularly in the areas of conducting clinical trials, obtaining market authorization, and facilitating the import and export of medicines.Du Kai expressed enthusiasm for deepening the collaboration between the pharmaceutical industries of both nations, fostering stronger commercial ties.

Throughout the exhibition, Gan & Lee's international business team engaged with numerous potential customers and partners. The team shared insights about the company's products and services while exploring future market opportunities within the pharmaceutical industry. These interactions laid a solid foundation for the company’s international market expansion and enhanced global cooperation.

Looking forward, Gan & Lee aims to further expand its global market presence, actively participating in international pharmaceutical collaborations and exchanges. The company remains committed to meeting customer needs and staying ahead of market trends, driving product innovation and R&D. With a focus on innovation and internationalization, Gan & Lee will continue to advance its global strategy in the pharmaceutical sector.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin®), fast-acting lispro injection (Prandilin), fast-acting aspart injection (Rapilin®), mixed protamine zinc lispro injection (25R) (Prandilin25), aspart 30 injection (Rapilin®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine®).


In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.


In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.





Copyright © 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP备10213074号-1 | 京公网安备 11011202003900号
Our websites


I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.